Rigel Pharmaceuticals RIGL Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Rigel Pharmaceuticals's unrealized gains on investments?
- Rigel Pharmaceuticals (RIGL) reported unrealized gains on investments of $42K in Q1 2026.
- What does unrealized gains on investments mean?
- This reflects the positive change in market value of available-for-sale securities that have not yet been sold. It represents potential future liquidity and unrealized wealth generated from the company's treasury management activities. Monitoring this provides insight into the performance of the firm's investment portfolio relative to market benchmarks.